IMMUNEONCO-B (01541.HK): First Patient Dosed in Phase II/III Trial of IMM0306 for IgG4-Related Disease

NewTimeSpace News: On 10 July 2026, IMMUNEONCO-B (01541.HK) released a voluntary announcement. The Phase II/III clinical trial of IMM0306, independently developed by the Company, for the treatment of IgG4-related disease (IgG4-RD) has successfully completed first patient dosing. The trial aims to evaluate the efficacy of IMM0306 in reducing disease relapse risk. The primary endpoint is disease relapse risk, and secondary endpoints include safety and tolerability.

IMM0306 is a bispecific molecule targeting CD47 and CD20. It is the world’s first CD47 and CD20 dual-targeted bispecific molecule entering clinical stage. It selectively eliminates malignant B cells by inhibiting the “don’t eat me” signal and activating macrophages and NK cells. IgG4-RD is a chronic progressive fibroinflammatory disorder that can affect multiple organs. Current immunosuppressive treatments are hampered by low response rates and high relapse rates, leaving significant unmet clinical needs. The Company stated that it holds global intellectual property rights and commercialisation rights for IMM0306, though there can be no assurance of successful development or marketing approval.